Skip to main content
Log in

Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study

  • Original Paper
  • Published:
International Orthopaedics Aims and scope Submit manuscript

Abstract

Purpose

Increasing numbers of atypical femoral fractures have been reported among long-term bisphosphonate users. We evaluated clinical characteristics of atypical femoral fractures throughout Korean multicenter studies.

Methods

We retrospectively analysed the bone mineral density, prodromal symptoms before femoral fracture, and medication history of osteoporosis in 76 cases of atypical femoral fracture.

Results

The mean age of cases was 71.4 ± 8.8 (range, 43–89) years old. The mean follow-up period after the fracture operation was 24.5 ± 12.9 (range, 12–79) months. BMI was 23.2 ± 3.0 on average. The mean BMD of femur was −1.9 ± 1.4 (range, −4.8 to 1.3). Prodromal symptoms including thigh pain before femoral fracture appeared in 22 (28.9 %) of 76 patients. All patients included in the study used bisphosphonate. The duration of taking bisphosphonate before fracture was 36.8 ± 50.8 (one–204 months) months. Fifty-seven (75 %) of 76 patients were taking the medication for more than three years. Delayed union occurred in 43 (56.5 %) of 76 patients. Delayed union was defined as a fractured bone that did not completely heal within six months of injury. The group of having taken anti-osteoporotic medication for more than three years showed relatively longer union period compared to that for a shorter period medication group (4.8 ± 2.5 months vs 9.3 ± 3.7 months, p = 0.017). The delayed union developed in 43 (56.5 %) of 76 patients and showed a significantly higher incidence in the group with long-term therapy (five/43 vs 38/43, p = 0.021). The bilateral femoral fractures developed in 23 (30.2 %) of 76 patients and showed a high incidence in the group medicated more than three years (two/23 vs 21/23, p = 0.039).

Conclusions

The longer bisphosphonates are used, the more the cases of delayed union and the more frequent the development of bilateral fractures following unilateral fractures. With regard to the delayed union, the methods of the acceleration of fracture healing may be beneficial in atypical femoral fracture patients who had been receiving long-term bisphosphonates therapy. Careful observation is required for contra-lateral femurs due to a high incidence of bilateral atypical femoral fractures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ioannidis G, Papaioannou A, Hopman WM et al (2009) Relation between fractures and mortality: results from the Canadian multicentre osteoporosis study. CMAJ 181(5):265–271

    Article  PubMed Central  PubMed  Google Scholar 

  2. Papaioannou A, Kennedy CC, Ioannidis G, CaMos Study Group et al (2009) The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian multicentre osteoporosis study. Osteoporos Int 20(5):703–714

    Article  CAS  PubMed  Google Scholar 

  3. Haentjens P, Magaziner J, Colon-Emeric CS et al (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152(6):380–390

    Article  PubMed Central  PubMed  Google Scholar 

  4. US Department of Health and Human Services (2004) Bone Health and Osteoporosis. A report of the surgeon general. US Dept of Health and Human Services, Office of the Surgeon General, Rockville

  5. Haleem S, Lutchman L, Mayahi R, Grice JE, Parker MJ (2008) Mortality following hip fracture: trends and geographical variations over the last 40 years. Injury 39(10):1157–1163

    Article  CAS  PubMed  Google Scholar 

  6. Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938

    Article  CAS  PubMed  Google Scholar 

  7. Neer RM (1995) Skeletal safety of tiludronate. Bone 17(Suppl):501S–503S

    Article  CAS  PubMed  Google Scholar 

  8. Lenart BA, Neviaser AS, Lyman S et al (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362

    Article  CAS  PubMed  Google Scholar 

  9. Schilcher J, Michaelsson K, Aspenberg P (2010) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737

    Article  Google Scholar 

  10. Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG (2012) Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br 94:385–390

    Article  CAS  PubMed  Google Scholar 

  11. Shane E, Burr D, Ebeling PR et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23. doi:10.1002/jbmr.1998

    PubMed  Google Scholar 

  12. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27:2544–2550

    Article  PubMed  Google Scholar 

  13. Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565

    Article  CAS  PubMed  Google Scholar 

  14. Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(11):2267–2294

    Article  PubMed  Google Scholar 

  15. Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49:34–41

    Article  CAS  PubMed  Google Scholar 

  16. Bukata SV, Kaback LA, Reynolds DG, Keefe RJ, Rosier RN (2009) 1–34 PTH at physiologic doses in humans shows promise as a helpful adjuvant in difficult to heal fractures: an observational cohort of 145 patients. Proceedings of the 55th Annual Meeting of the Orthopaedic Research Society, February 22–25, Las Vegas

  17. Aspenberg P, Genant HK, Johansson T, Nino AJ, See K et al (2010) Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Mineral Res 25:404–414

    Article  CAS  Google Scholar 

  18. Rubin C, Bolander M, Ryaby JP, Hadjiargyrou M (2001) The use of low intensity ultrasound to accelerate the healing of fractures. J Bone Joint Surg Am 83-A:259–270

    CAS  PubMed  Google Scholar 

  19. Jingushi S, Mizuno K, Matsushita T, Itoman M (2007) Low-intensity pulsed ultrasound treatment for postoperative delayed union or nonunion of long bone fractures. J Orthop Sci 12:35–41

    Article  PubMed  Google Scholar 

  20. De Das S, Setiobudi T, Shen L, De Das S (2010) A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br 92:679–686

    Article  Google Scholar 

  21. Ha YC, Cho MR, Park KH, Kim SY, Koo KH (2010) Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res 468:3393–3398

    Article  PubMed Central  PubMed  Google Scholar 

  22. Capeci CM, Tejwani NC (2009) Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 91:2556–2561

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None to declare.

Ethical review committee statement

This multicenter study was approved by the institutional review board of the authors’ institute.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Joon Soon Kang or Young Tae Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kang, J.S., Won, Y.Y., Kim, J.O. et al. Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study. International Orthopaedics (SICOT) 38, 1247–1253 (2014). https://doi.org/10.1007/s00264-013-2259-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00264-013-2259-9

Keywords

Navigation